文献速递消化、代谢与肾脏急症

伊沙妥昔单抗联合泊马度胺及低剂量地塞米松对比泊马度胺及低剂量地塞米松治疗复发难治性多发性骨髓瘤(ICARIA-MM):一项随机、多中心、开放标签、3期研究

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
PubMed 文献 · Lancet · 2019-11-14
一句话结论在复发难治性多发性骨髓瘤患者中,伊沙妥昔单抗联合泊马度胺及地塞米松较单用泊马度胺及地塞米松显著延长无进展生存期(中位11.5 vs 6.5个月,HR 0.596)。

ICARIA-MM是一项在24个国家102家医院开展的随机、多中心、开放标签3期研究,纳入307例既往至少接受过两线治疗(包括来那度胺和蛋白酶体抑制剂)的复发难治性多发性骨髓瘤成人患者,排除对既往抗CD38单抗耐药者。患者1:1随机接受伊沙妥昔单抗10 mg/kg联合泊马度胺4 mg及地塞米松40 mg(≥75岁者20 mg)或单用泊马度胺及地塞米松。中位随访11.6个月,联合组中位无进展生存期11.5个月(95%CI 8.9-13.9)vs 对照组6.5个月(95%CI 4.5-8.3),HR 0.596(95%CI 0.44-0.81),p=0.001。联合组输液反应发生率38%(56例)vs 0%。研究者认为,伊沙妥昔单抗联合方案显著改善无进展生存期,是复发难治性骨髓瘤的重要新治疗选择,尤其适用于对来那度胺和蛋白酶体抑制剂耐药的患者。

要点

  • 纳入既往至少两线治疗(含来那度胺和蛋白酶体抑制剂)的复发难治性多发性骨髓瘤成人患者,排除对既往抗CD38单抗耐药者。
  • 伊沙妥昔单抗联合组中位无进展生存期11.5个月(95%CI 8.9-13.9)vs 对照组6.5个月(95%CI 4.5-8.3),HR 0.596(95%CI 0.44-0.81),p=0.001。
  • 联合组输液反应发生率38%(56例)vs 对照组0%,上呼吸道感染28%(43例)vs 17%(26例),腹泻26%(39例)vs 20%(29例)。
  • 联合组致死性不良事件8%(12例)vs 对照组9%(14例);治疗相关死亡联合组<1%(1例,脓毒症)vs 对照组1%(2例,肺炎和尿路感染)。
  • 伊沙妥昔单抗10 mg/kg静脉给药,首周期第1、8、15、22天,后续周期第1、15天;泊马度胺4 mg口服每周期第1-21天;地塞米松40 mg(≥75岁20 mg)口服或静脉每周期第1、8、15、22天。

适用人群与场景

  • 成人复发难治性多发性骨髓瘤患者,既往至少接受过两线治疗,包括来那度胺和蛋白酶体抑制剂。
  • 排除对既往抗CD38单克隆抗体治疗耐药的患者。

处置流程与药物剂量

  • 伊沙妥昔单抗10 mg/kg静脉给药,第一周期28天第1、8、15、22天,后续周期第1、15天。
  • 泊马度胺4 mg口服,每周期第1-21天。
  • 地塞米松40 mg(≥75岁患者20 mg)口服或静脉,每周期第1、8、15、22天。
  • 治疗持续至疾病进展、不可接受毒性或撤回知情同意;泊马度胺和地塞米松允许因不良反应减量,伊沙妥昔单抗不允许减量。

研究设计与关键结果

  • 随机、多中心、开放标签3期研究,在24个国家102家医院纳入307例患者,1:1随机分配至伊沙妥昔单抗联合组(154例)或对照组(153例)。
  • 中位随访11.6个月(IQR 10.1-13.9),联合组中位无进展生存期11.5个月(95%CI 8.9-13.9)vs 对照组6.5个月(95%CI 4.5-8.3),HR 0.596(95%CI 0.44-0.81),p=0.001(分层log-rank检验)。
  • 最常见治疗中出现的不良事件(任何级别;联合组 vs 对照组):输液反应56例(38%)vs 0例,上呼吸道感染43例(28%)vs 26例(17%),腹泻39例(26%)vs 29例(20%)。
  • 致死性不良事件:联合组12例(8%)vs 对照组14例(9%);治疗相关死亡:联合组1例(<1%,脓毒症)vs 对照组2例(1%,肺炎和尿路感染)。

证据类型、等级与局限

  • 证据类型:随机、多中心、开放标签3期研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在泊马度胺-地塞米松基础上加用伊沙妥昔单抗可显著改善复发难治性多发性骨髓瘤患者的无进展生存期。
  • 作者认为,伊沙妥昔单抗是复发难治性骨髓瘤管理的重要新治疗选择,尤其适用于对来那度胺和蛋白酶体抑制剂耐药的患者。
  • 联合组输液反应发生率为38%,对照组为0%,用药时需注意输液反应监测。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous phase 1b study, around 65% of patients with relapsed and refractory multiple myeloma achieved an overall response with a combination of isatuximab with pomalidomide and low-dose dexamethasone. The aim of this study was to determine the progression-free survival benefit of isatuximab plus pomalidomide and dexamethasone compared with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma.

METHODS: We did a randomised, multicentre, open-label, phase 3 study at 102 hospitals in 24 countries in Europe, North America, and the Asia-Pacific regions. Eligible participants were adult patients with relapsed and refractory multiple myeloma who had received at least two previous lines of treatment, including lenalidomide and a proteasome inhibitor. Patients were excluded if they were refractory to previous treatment with an anti-CD38 monoclonal antibody. We randomly assigned patients (1:1) to either isatuximab 10 mg/kg plus pomalidomide 4 mg plus dexamethasone 40 mg (20 mg for patients aged ≥75 years), or pomalidomide 4 mg plus dexamethasone 40 mg. Randomisation was done using interactive response technology and stratified according to the number of previous lines of treatment (2-3 vs >3) and age (<75 years vs ≥75 years). Treatments were assigned based on a permuted blocked randomisation scheme with a block size of four. The isatuximab-pomalidomide-dexamethasone group received isatuximab intravenously on days 1, 8, 15, and 22 in the first 28-day cycle, then on days 1 and 15 in subsequent cycles. Both groups received oral pomalidomide on days 1 to 21 in each cycle, and oral or intravenous dexamethasone on days 1, 8, 15, and 22 of each cycle. Treatment continued until disease progression, unacceptable toxicity, or consent withdrawal. Dose reductions for adverse reactions were permitted for pomalidomide and dexamethasone, but not for isatuximab. The primary endpoint was progression-free survival, determined by an independent response committee and assessed in the intention-to-treat population. Safety was assessed in all participants who received at least one dose of study drug. This study is registered at ClinicalTrials.gov, number NCT02990338.

FINDINGS: Between Jan 10, 2017, and Feb 2, 2018, we randomly assigned 307 patients to treatment: 154 to isatuximab-pomalidomide-dexamethasone, and 153 to pomalidomide-dexamethasone. At a median follow-up of 11·6 months (IQR 10·1-13·9), median progression-free survival was 11·5 months (95% CI 8·9-13·9) in the isatuximab-pomalidomide-dexamethasone group versus 6·5 months (4·5-8·3) in the pomalidomide-dexamethasone group; hazard ratio 0·596, 95% CI 0·44-0·81; p=0·001 by stratified log-rank test. The most frequent treatment-emergent adverse events (any grade; isatuximab-pomalidomide-dexamethasone vs pomalidomide-dexamethasone) were infusion reactions (56 [38%] vs 0), upper respiratory tract infections (43 [28%] vs 26 [17%]), and diarrhoea (39 [26%] vs 29 [20%]). Adverse events with a fatal outcome were reported in 12 patients (8%) in the isatuximab-pomalidomide-dexamethasone group and 14 (9%) in the pomalidomide-dexamethasone group. Deaths due to treatment-related adverse events were reported for one patient (<1%) in the isatuximab-pomalidomide-dexamethasone group (sepsis) and two (1%) in the pomalidomide-dexamethasone group (pneumonia and urinary tract infection).

INTERPRETATION: The addition of isatuximab to pomalidomide-dexamethasone significantly improves progression-free survival in patients with relapsed and refractory multiple myeloma. Isatuximab is an important new treatment option for the management of relapsed and refractory myeloma, particularly for patients who become refractory to lenalidomide and a proteasome inhibitor.

FUNDING: Sanofi. VIDEO ABSTRACT.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019. PMID: 31735560. doi:10.1016/S0140-6736(19)32556-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。